论文部分内容阅读
目的:探索帕金森病(Parkinson’s disease,PD)患者血浆中α-突触核蛋白、Aβ及tau蛋白变化情况。方法:募集2014年4月至2015年4月来我院就诊的PD患者62例,正常对照人群59例,采集两组人群的基本临床信息,测定血浆中α-突触核蛋白、Aβ40、Aβ42、p T181-tau蛋白、p T231-tau蛋白和总tau蛋白浓度,比较两组之间的差异,同时进行相关性分析。结果:PD患者血浆α-突触核蛋白和p T181-tau蛋白浓度显著高于对照组(P值分别为0.001,0.019),而两组间Aβ40、Aβ42、p T231-tau蛋白和总tau蛋白浓度无明显差异(P>0.05)。相关性分析提示PD患者血浆α-突触核蛋白和p T181-tau蛋白浓度与患者年龄、性别、教育程度、病程、高血压、糖尿病、Hoehn/Yahr分级及Schwab&England评分无相关性(P>0.05)。结论:虽然PD患者血浆α-突触核蛋白和p T181-tau蛋白高于正常对照组,但尚不适宜作为PD的生物标志物。
Objective: To explore the changes of plasma α-synuclein, Aβ and tau in patients with Parkinson’s disease (PD). Methods: 62 cases of PD patients and 59 normal control subjects from April 2014 to April 2015 were enrolled in this study. The basic clinical information of two groups were collected and the levels of α-synuclein, Aβ40, Aβ42 , PT181-tau protein, pT231-tau protein and total tau protein concentration were compared between the two groups, while the correlation analysis. Results: The plasma levels of α-synuclein and pT181-tau in PD patients were significantly higher than those in controls (P = 0.001,0.019, respectively). However, the Aβ40, Aβ42, No significant difference in concentration (P> 0.05). Correlation analysis indicated that plasma concentrations of α-synuclein and pT181-tau in PD patients were not related to age, gender, education level, duration of disease, hypertension, diabetes, Hoehn / Yahr grading and Schwab & England scores (P> 0.05 ). Conclusions: Although the plasma levels of α-synuclein and pT181-tau in PD patients are higher than those in normal controls, they are not suitable as PD biomarkers.